Published in Nat Biotechnol on October 20, 2013
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary | NCT02628379
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol (2015) 4.97
Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med (2014) 3.75
Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med (2015) 2.88
Individualized medicine from prewomb to tomb. Cell (2014) 2.76
High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell (2016) 2.31
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res (2015) 2.12
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov (2015) 2.07
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol (2015) 1.73
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. J Clin Oncol (2015) 1.73
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist (2014) 1.71
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood (2016) 1.66
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov (2015) 1.64
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist (2014) 1.61
The current state of resident training in genomic pathology: a comprehensive analysis using the resident in-service examination. Am J Clin Pathol (2014) 1.56
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol (2015) 1.56
Integrative molecular profiling of routine clinical prostate cancer specimens. Ann Oncol (2015) 1.51
Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia (2015) 1.44
Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors. Elife (2015) 1.42
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget (2016) 1.41
Comparing two assays for clinical genomic profiling: the devil is in the data. Onco Targets Ther (2015) 1.39
Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A (2014) 1.38
Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res (2015) 1.35
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov (2016) 1.26
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol (2014) 1.26
Haplotyping germline and cancer genomes with high-throughput linked-read sequencing. Nat Biotechnol (2016) 1.25
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep (2014) 1.21
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discov (2015) 1.17
Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem (2015) 1.16
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One (2015) 1.15
Patient-centric trials for therapeutic development in precision oncology. Nature (2015) 1.14
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol (2014) 1.12
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol (2015) 1.12
Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol (2014) 1.12
Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol (2014) 1.12
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res (2014) 1.09
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res (2015) 1.09
Next-generation sequencing in the clinic. Nat Biotechnol (2013) 1.09
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res (2015) 1.07
STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. J Hematol Oncol (2015) 1.05
ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics (2014) 1.04
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs (2014) 1.04
Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun (2015) 1.02
Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood (2015) 1.01
Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes. Front Genet (2015) 1.01
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov (2015) 1.01
Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing. Hum Mutat (2015) 1.00
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene (2014) 1.00
Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treat Commun (2015) 0.99
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell Melanoma Res (2014) 0.98
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer (2015) 0.98
Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin (2015) 0.97
EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discov (2015) 0.96
Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol (2015) 0.96
Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel. BMC Med Genomics (2014) 0.95
Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies. ACS Biomater Sci Eng (2015) 0.95
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res (2016) 0.95
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer (2015) 0.94
Achieving high-sensitivity for clinical applications using augmented exome sequencing. Genome Med (2015) 0.94
Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. Br J Cancer (2015) 0.94
Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection. Cancers (Basel) (2015) 0.94
A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Oncologist (2014) 0.93
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist (2016) 0.93
Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist (2015) 0.92
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol (2016) 0.92
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Mol Cell Proteomics (2015) 0.92
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med (2016) 0.92
Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors. Exp Mol Pathol (2015) 0.92
Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget (2015) 0.91
Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Mod Pathol (2015) 0.91
Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads. Nat Biotechnol (2014) 0.91
Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnostics. PLoS One (2014) 0.90
VisCap: inference and visualization of germ-line copy-number variants from targeted clinical sequencing data. Genet Med (2015) 0.89
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunol Res (2016) 0.88
Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta (2015) 0.88
Low-level constitutional mosaicism of a de novoBRCA1 gene mutation. Br J Cancer (2015) 0.88
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors. Cancer Discov (2015) 0.88
Genomic and Epigenomic Alterations in Cancer. Am J Pathol (2016) 0.86
Colorectal cancer in the young, many questions, few answers. World J Gastrointest Oncol (2016) 0.86
Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol (2015) 0.86
Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies. Cancers (Basel) (2015) 0.85
Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). BMC Genomics (2015) 0.85
Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget (2015) 0.85
Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations. J Mol Diagn (2015) 0.85
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov (2016) 0.85
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? J Thorac Oncol (2016) 0.85
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist (2015) 0.84
Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med (2016) 0.84
Cancer: A most exceptional response. Nature (2015) 0.84
EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discov (2016) 0.84
Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC. PLoS One (2015) 0.84
A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma. Sci Rep (2016) 0.84
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discov (2016) 0.84
Systematic discovery of complex insertions and deletions in human cancers. Nat Med (2015) 0.83
Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist (2014) 0.83
Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. Oncologist (2015) 0.83
Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary. Case Rep Oncol (2014) 0.83
FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. J Transl Med (2016) 0.83
Amplicon sequencing of colorectal cancer: variant calling in frozen and formalin-fixed samples. PLoS One (2015) 0.82
Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight (2016) 0.82
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res (2001) 76.97
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics (2010) 52.01
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
The UCSC Table Browser data retrieval tool. Nucleic Acids Res (2004) 25.12
The cancer genome. Nature (2009) 23.13
International network of cancer genome projects. Nature (2010) 20.35
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
The life history of 21 breast cancers. Cell (2012) 10.59
Dindel: accurate indel calls from short-read data. Genome Res (2010) 8.62
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
1000 Genomes project. Nat Biotechnol (2008) 5.73
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol (2011) 5.11
Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72
Translating insights from the cancer genome into clinical practice. Nature (2008) 4.37
Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol (2012) 3.62
How to apply de Bruijn graphs to genome assembly. Nat Biotechnol (2011) 3.36
Clinical implications of the cancer genome. J Clin Oncol (2010) 3.11
A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol (2010) 2.72
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2012) 2.39
Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res (2013) 2.29
Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn (2013) 2.27
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics (2011) 2.24
Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn (2012) 1.92
Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther (2010) 1.77
Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther (2012) 1.72
Genome sequencing and cancer. Curr Opin Genet Dev (2012) 1.68
Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol (2006) 1.62
Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood (2012) 1.38
Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol (2012) 1.32
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21
New approaches to targeted therapy in lung cancer. Proc Am Thorac Soc (2012) 1.04
Immunohistochemistry in the era of personalised medicine. J Clin Pathol (2012) 0.98
Update on HER2 testing for breast and upper gastrointestinal tract cancers. Biomark Med (2011) 0.97
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest (2003) 32.01
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Efficiency and power in genetic association studies. Nat Genet (2005) 25.56
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
A large genome center's improvements to the Illumina sequencing system. Nat Methods (2008) 15.56
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Evaluating and improving power in whole-genome association studies using fixed marker sets. Nat Genet (2006) 14.76
Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66
Rare variants create synthetic genome-wide associations. PLoS Biol (2010) 14.43
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Genotype, haplotype and copy-number variation in worldwide human populations. Nature (2008) 12.40
GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics (2009) 12.01
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Single-molecule DNA sequencing of a viral genome. Science (2008) 11.66
Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet Epidemiol (2008) 11.28
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
The life history of 21 breast cancers. Cell (2012) 10.59
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature (2009) 9.47
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
Diversity and complexity in DNA recognition by transcription factors. Science (2009) 9.07
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet (2012) 7.31
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A (2008) 7.22
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
The microRNA spectrum in 12 body fluids. Clin Chem (2010) 6.82
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Rapid analysis of the DNA-binding specificities of transcription factors with DNA microarrays. Nat Genet (2004) 6.33
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist (2009) 6.00
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res (2006) 5.69
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64